The use of therapeutic molecules targeting the neonatal Fc receptor (FcRn) aims at the selective removal of immunoglobulin G (IgG), a process that is also widely performed by plasmapheresis in patients with myasthenia gravis (MG). The gene discussed is FCGRT; the disease is myasthenia gravis.